XML 32 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 85,468,796 $ 40,543,982
Short-term investments 85,313,556 53,075,974
Accounts receivable 10,965,273 2,804,207
Prepaid expenses and other current assets 1,348,890 797,973
Prepaid expenses and other current assets from affiliated entity 634,326 1,382,375
Deferred tax asset 342,573 342,573
Total current assets 184,073,414 98,947,084
Fixed assets, net 6,458,900 4,583,204
Investments in affiliated entities 25,321,361 12,340,811
Intangible assets, net 4,118,010 4,776,059
Goodwill 10,113,371 10,113,371
Common stock warrants 88,900 550,000
Other assets 597,570 474,568
Total assets 230,771,526 131,785,097
Current liabilities:    
Accounts payable and accrued expenses 10,519,408 6,383,170
Accounts payable and accrued expenses due to affiliated entity 2,813,019 28,407
Accrued clinical trial expenses 2,942,444 2,007,432
Common stock warrants 1,093,752 2,022,729
Deferred revenue 188,415 3,187,223
Deferred revenue from affiliated entity 523,192 394,791
Deferred rent 197,642 0
Total current liabilities 18,277,872 14,023,752
Deferred revenue, net of current portion 12,798,493 173,779
Deferred revenue from affiliated entity, net of current portion 798,532 836,694
Deferred rent, net of current portion 5,007,000 4,709,229
Deferred tax liabilities 504,049 504,049
Total liabilities 37,385,946 20,247,503
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 72,181 60,741
Additional paid-in capital 532,559,242 443,327,915
Accumulated deficit (343,145,851) (331,910,290)
Accumulated other comprehensive income (loss) 3,654,180 (251,390)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 193,139,752 111,226,976
Non-controlling interest 245,828 310,618
Total stockholders’ equity 193,385,580 111,537,594
Total liabilities and stockholders’ equity $ 230,771,526 $ 131,785,097